Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
With a pediatric approval in hand for Afrezza, MannKind believes that it finally has the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insu | With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insulin powder.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

The FDA has approved technosphere insulin, an inhaled form of human insulin, for children and adolescents aged 6 years and older…

Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…

Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal

After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for…

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…

Despite unprecedented access to data and AI, many life sciences organizations still struggle to make confident commercial…